La définition de la resténose vue par le clinicien : aspects méthodologiques et angiographiques = Restenosis estimation at the clinical level: methodologic and angiographic aspectsJULIARD, J.-M; STEG, P. Gabriel.Pathologie et biologie. 2004, Vol 52, Num 4, pp 180-185, issn 0369-8114, 6 p.Article

Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction : a comprehensive meta-analysis of randomized trials. CommentarySTEG, P. Gabriel; DUCROCQ, Gregory; BAVRY, Anthony A et al.European heart journal. 2008, Vol 29, Num 24, issn 0195-668X, 2953-2954, 2989-3001 [15 p.]Article

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: Short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trialSCULPHER, Mark J; LOZANO-ORTEGA, Greta; SAMBROOK, Jennifer et al.The American heart journal. 2009, Vol 157, Num 5, pp 845-852, issn 0002-8703, 8 p.Article

Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid : Determinants and Effect on Cardiovascular RiskEIKELBOOM, John W; HANKEY, Graeme J; HAMM, Christian et al.Circulation (New York, N.Y.). 2008, Vol 118, Num 17, pp 1705-1712, issn 0009-7322, 8 p.Article

Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarctionHUISSE, Marie-Geneviève; LANOY, Emilie; TCHECHE, Didier et al.Thrombosis and haemostasis. 2007, Vol 98, Num 2, pp 420-426, issn 0340-6245, 7 p.Article

Enoxaparin versus unfractionated heparin in elective percutaneous coronary interventionMONTALESCOT, Gilles; WHITE, Harvey D; DESMET, Walter J et al.The New England journal of medicine. 2006, Vol 355, Num 10, pp 1006-1017, issn 0028-4793, 12 p.Article

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsMAURI, Laura; KEREIAKES, Dean J; HOLMES, David R et al.The New England journal of medicine. 2014, Vol 371, Num 23, pp 2155-2166, issn 0028-4793, 12 p.Article

Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsSIMON, Tabassome; VERSTUYFT, Celine; MARY-KRAUSE, Murielle et al.The New England journal of medicine. 2009, Vol 360, Num 4, pp 363-375, issn 0028-4793, 13 p.Article

Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular DiseaseBERGER, Jeffrey S; BHATT, Deepak L; BERGER, Peter B et al.Circulation (New York, N.Y.). 2009, Vol 120, Num 23, pp 2337-2344, issn 0009-7322, 8 p.Article

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trialTOPOL, Eric J; BOUSSER, Marie-Germaine; COHEN, Eric et al.Lancet (British edition). 2010, Vol 376, Num 9740, pp 517-523, issn 0140-6736, 7 p.Article

Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT)LANG, Irene M; FORMAN, Sandra A; SOPKO, George et al.EuroIntervention. 2009, Vol 5, Num 5, pp 610-618, issn 1774-024X, 9 p.Article

Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)DASGUPTA, Arijit; STEINHUBL, Stewen R; DIMAS, Alexios P et al.The American journal of cardiology. 2009, Vol 103, Num 10, pp 1359-1363, issn 0002-9149, 5 p.Article

Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction : insights from the GUSTO-V trialKAUL, Padma; CHANG, Wei-Ching; VAN DE WERF, Frans et al.European heart journal. 2006, Vol 27, Num 10, pp 1198-1206, issn 0195-668X, 9 p.Article

Mortality at 1 year with Combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialLINCOFF, A. Michael; CALIFF, Robert M; VAHANIAN, Alec et al.JAMA, the journal of the American Medical Association. 2002, Vol 288, Num 17, pp 2130-2135, issn 0098-7484, 6 p.Article

An Education Program for Risk Factor Management After an Acute Coronary Syndrome A Randomized Clinical TrialCOHEN, Ariel; ASSYAG, Patrick; BOUTRON, Isabelle et al.JAMA internal medicine (Print). 2014, Vol 174, Num 1, pp 40-50, issn 2168-6106, 11 p.Article

Darapladib for Preventing Ischemic Events in Stable Coronary Heart DiseaseWHITE, Harvey D; HELD, Claes; ARMSTRONG, Paul W et al.The New England journal of medicine. 2014, Vol 370, Num 18, pp 1702-1711, issn 0028-4793, 10 p.Article

Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registryTENDERA, Michal; FOX, Kim; STEG, P. Gabriel et al.International journal of cardiology. 2014, Vol 176, Num 1, pp 119-124, issn 0167-5273, 6 p.Article

Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialBERGER, Jeffrey S; BHATT, Deepak L; LINCOFF, A. Michael et al.The American heart journal. 2011, Vol 162, Num 1, pp 98-105, issn 0002-8703, 8 p.Article

Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy: Insights From a Propensity-Matched Analysis of the Reduction of Atherothrombosis for Continued Health (REACH) RegistryBANGALORE, Sripal; BHATT, Deepak L; TOPAKIAN, Raffi et al.Circulation (New York, N.Y.). 2010, Vol 122, Num 11, pp 1091-1100, issn 0009-7322, 10 p.Article

Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST-and Non-ST-Segment Elevation Acute Coronary Syndromes : An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized TrialsMEHTA, Shamir R; BODEN, William E; CHROLAVICIUS, Susan et al.Circulation (New York, N.Y.). 2008, Vol 118, Num 20, pp 2038-2046, issn 0009-7322, 9 p.Article

Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: Insights from The Global Registry of Acute Coronary EventsBRIEGER, David; EAGLE, Kim A; GOODMAN, Shaun G et al.Chest. 2004, Vol 126, Num 2, pp 461-469, issn 0012-3692, 9 p.Article

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusSCIRICA, Benjamin M; BHATT, Deepak L; CAVENDER, Matthew A et al.The New England journal of medicine. 2013, Vol 369, Num 14, pp 1317-1326, issn 0028-4793, 10 p.Article

Thiazolidinedione use is not associated with worse cardiovascular outcomes: A study in 28,332 high risk patients with diabetes in routine clinical practice Brief title: Thiazolidinedione use and mortalityROUSSEL, Ronan; HADJADJ, Samy; BHATT, Deepak L et al.International journal of cardiology. 2013, Vol 167, Num 4, pp 1380-1384, issn 0167-5273, 5 p.Article

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI : A Meta-analysisMEGA, Jessica L; SIMON, Tabassome; HORNE, Benjamin D et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 16, pp 1821-1830, issn 0098-7484, 10 p.Article

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo-controlled trial. CommentaryREIL, Jan-Christian; BOHM, Michael; FOX, Kim et al.Lancet (British edition). 2008, Vol 372, Num 9641, issn 0140-6736, 779-780, 807-816 [12 p.]Article